In immunology, AbbVie's flagship drug, Humira, recorded a sales decline of 28.9% to $2.81 billion. Sales in the United States declined 31.6% to $2.36 billion, while ex-U.S. market sales were down 12.5% on an operating basis to $454 million. While the drug's sales beatthe Zacks Consensus Estimate of $2.79 billion, it was nearly in line with our model estimates of $2.81 billion.